We reached an
oral agreement.
我们达成了口头协议。
Diet is also a risk factor.
饮食也是一个危险因素。
Mary's appearance always acted as a damper to the curiosity raised by her
oral oddities.
她的外表常常会消除她口头的怪癖所引起的好奇。
During last year's CIIE, Pfizer's antiviral oral therapeutic drug for COVID-19 Paxlovid made its debut in China.
在去年的CIIE期间，辉瑞公司针对新冠肺炎的抗病毒口服治疗药物奈玛特韦片/利托那韦片组合包装首次在中国上市。
The company has also brought a host of newly developed nutrition products, including one developed and produced in China for the maintenance of muscle mass in people older than 50 years, and an OTC oral contraceptive pill.
该公司还带来了一系列新开发的营养产品，包括一种在中国开发和生产的用于维持50岁以上人群肌肉质量的营养产品和一种非处方口服避孕药。
They include the world's first oral targeted drug for psoriasis Otezla, the third-generation COMT inhibitor Ongentys to treat Parkinson's disease, and a home beauty instrument, LMNT one, which was developed with Israel's energy source technology, according to Yi Jinyuan, general manager of public relations at Fosun Pharma.
复星医药公共关系总经理易金元表示，其中包括世界上第一种治疗银屑病的口服靶向药物Otezla，治疗帕金森病的第三代COMT抑制剂Ongentys，以及使用以色列能源技术开发的家用美容仪LMNT one。
Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday.
周日，全球生物制药公司辉瑞在中国举行了Cibinqo的上市仪式。Cibinqo是一种口服的、每天一次的高选择性JAK1（Janus激酶1）抑制剂，用于治疗中重度特应性皮炎的成年患者。
The Geneva-based Medicines Patent Pool's offer of a non-exclusive sublicense to several Chinese enterprises to produce the generic version of Pfizer's oral COVID-19 treatment can help mitigate poor access to COVID-19 medicines, industry experts and business leaders said on Friday, adding the offer is also a recognition of the Chinese makers' capability to produce high-quality drugs.
行业专家和商界领袖周五表示，基于基因的药物专利库向几家中国企业提供非排他性转授许可，以生产辉瑞口服新冠肺炎的仿制药，这有助于缓解新冠肺炎药物的获取困难，并补充说，这一提议也是对中国制造商生产高质量药物能力的认可。
The nirmatrelvir tablets and ritonavir tablets combination is a co-packaged oral COVID-19 treatment under the brand Paxlovid.
nirmatrevir片剂和利托那韦片剂组合是奈玛特韦片/利托那韦片组合包装品牌的新冠肺炎联合包装口服治疗。
In February, the National Medical Products Administration, China's top drug regulator, gave conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral pill for the disease approved in the country.
今年2月，中国最高药品监管机构国家药品监督管理局有条件批准了辉瑞公司的新冠肺炎治疗药物奈玛特韦片/利托那韦片组合包装，使其成为中国批准的第一种口服药物。
"Clinical data of the oral capsule in the US has so far shown results that are completely consistent with that in China, which fully reflects its stability," said Su Weiguo, executive director, CEO and chief scientific officer of HUTCHMED.
HUTCHMED执行董事、首席执行官兼首席科学官苏卫国表示：“迄今为止，美国口服胶囊的临床数据显示，其结果与中国完全一致，这充分反映了其稳定性。”。
Sales of the oral anticoagulant Xarelto™ grew by 6.0 percent (Fx& portfolio adj.
口服抗凝剂Xarelto™的销售额增长了6.0%（Fx和投资组合调整。
The consumer goods unit of the United States-based Johnson & Johnson will deploy more resources in digitalization and innovation to further expand its sales of skincare, oral and baby care products in China this year, said a senior executive.
一位高管表示，总部位于美国的强生公司的消费品部门今年将在数字化和创新方面部署更多资源，以进一步扩大其在中国的护肤品、口腔护理和婴儿护理产品的销售。
Given China's soaring demand for consumer health items, as well as its strategic importance, Wang said Johnson & Johnson will introduce more health-oriented innovative products into China in the coming years, aiming at making consumers healthier in skin, oral and hair to bring all-around outer beauty.
王表示，鉴于中国消费者对健康产品的需求激增，以及其战略重要性，强生公司将在未来几年向中国推出更多以健康为导向的创新产品，旨在让消费者在皮肤、口腔和头发方面更健康，带来全方位的外表美。
Booming sales of power brush in nation attract more investment, participationUnited States oral hygiene brand Oral-B, a sub-brand of drug giant Procter & Gamble, is stepping up its push to tap Generation Z consumers in China, which has been the world's largest market for electric toothbrushes since last year.
电动牙刷在中国的蓬勃销售吸引了更多的投资，美国口腔卫生品牌oral-B，制药巨头宝洁的子品牌，正在加紧努力挖掘中国的Z世代消费者，自去年以来，中国一直是世界上最大的电动牙刷市场。
There is still huge upside to this market, given that only 10 percent of consumers are using power brushes today, said Vedran Miletic, president of P&G Greater China Oral Care.
宝洁大中华区口腔护理总裁Vedran Miletic表示，鉴于目前只有10%的消费者使用电动牙刷，这个市场仍有巨大的优势。
"Oral B has strategically chosen to invest in social platforms like Douyin, Little Red Book and Bilibili to engage with customers in a deeper manner.
“口腔B已战略性地选择投资抖音、小红书和哔哩哔哩等社交平台，以更深入的方式与客户互动。
Eyeing opportunities from smart homes, a string of Chinese consumer electronics brands such as Huawei and Xiaomi have branched into the electric toothbrush market, and domestic oral care companies are also emerging as competitive players.
看到智能家居的机遇，华为和小米等一系列中国消费电子品牌已经进军电动牙刷市场，国内口腔护理公司也正在成为竞争对手。
This indicates that Chinese consumers find oral health very important, and that this market has great potential," Miletic said.
这表明中国消费者发现口腔健康非常重要，而且这个市场有很大的潜力，”Miletic说。
"We also have a full line of oral care products, like toothpaste, rinse and floss, covering different price ranges to meet different consumer needs.
“我们还有全系列的口腔护理产品，如牙膏、漱口液和牙线，涵盖不同的价格范围，以满足不同的消费者需求。
"In the future, Oral-B will continue to innovate in oral care technology to fulfill Chinese consumer needs, and we hope to bring more professional oral care products to consumers," Miletic added.
Miletic补充道：“未来，Oral-B将继续在口腔护理技术方面进行创新，以满足中国消费者的需求，我们希望为消费者带来更专业的口腔护理产品。”。
Visitors are likely to be drawn by the first oral antiviral medicine against COVID-19 if and when it's approved by FDA.
For instance, the new drug application of an oral innovative drug for lung cancer was given a priority review designation, leading to simultaneous submissions to National Drug Authority in China and globally.
The COVID-19 pandemic has also pushed the growth potential of the stay-at-home economy, as more people stay home longer and purchase more personal health products such as eye and oral health, skin care and other products, Chines said.
The company's oral drug Selinexor, which works in a mechanism different from all existing approved therapies, was approved on July 29 in South Korea, the first overseas market in Asia, to treat relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma, a form of cancer.
On July 29, the company's oral drug Selinexor, which works in a mechanism different from all the existing approved therapies, was approved in South Korea, the first overseas market in Asia, to treat relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma.
The drug was the first innovative intravenous iron approved in China since 2005, when the National Medical Products Administration approved it in February for the treatment of iron deficiency and iron-deficiency anemia in adult patients who have an intolerance to oral iron, have had an unsatisfactory response to oral iron, or when there is a clinical need to deliver iron rapidly.
Several advanced oral anti-virus medicines have been launched in China, which is significant for the country to eliminate hepatitis C before 2030, she added.
The COVID-19 pandemic has also pushed the growth potential of the stay-at-home economy, as more people stay at home longer and purchase more personal health products such as oral health, skin care and other products these days, said Khanna, who is also a member of the Philips' executive committee.
The company also said a rolling submission of a new drug application of the oral capsule Surufatinib, an innovative oncology drug with independent research and development efforts, was initiated with the United States Food and Drug Administration in late December, and its marketing authorization application in Europe is being prepared.
Its core businesses currently include an online livestreaming course, an oral arithmetic calculation app and Paperang, a hardware product to search for answers to questions and help users take photos.
Xiu Jiaming, head of teaching and research at Zebra AI, said its users are in over 400 cities nationwide and the company has accumulated 75 exclusive patents, which are applied into steps, including oral evaluation, AI interactive class and adaptive question generation.
In recent years, with the rapid development of disease awareness and diagnostic approaches, the widespread use of oral medication and other treatment modalities has improved the effect of hemorrhoids treatment, significantly relieving symptoms and reducing recurrence.
The therapy, the first and only single-dose oral drug approved for the treatment of influenza and the first anti-influenza drug approved by the United States Food and Drug Administration, is also being showcased at the expo.
- Boosted by the China International Import Expo (CIIE), China is becoming one of the fastest growing consumer markets for the New Zealand oral care products, New Zealand entrepreneurs said on Thursday.
Mark Hitchcock, general manager of New Zealand oral care brand Grin Natural, who is now busy working on the company's presence in the upcoming CIIE in November, told Xinhua that the Chinese market represented about one third of its export volume and was growing fast.
"China is such an exciting market for us as we are seeing a huge increase in the awareness of the importance of oral care.
Started from 2015, the Auckland-based company, which exports oral care products as toothpastes and toothbrushes made with natural ingredients, now boasts annual sales volume worth of 26.7 million New Zealand dollars.
"Interestingly the area they are in is oral care.
In some ways it's like an extension of the sort of healthcare category extending into oral care and to hand sanitizer.
Healthcare products and food consumption is a reflection of economic success, he said, adding oral care and dental product usage is rising.
The firm produced 1,000 metric tons of high-end oral health products in 2018.
It is also upgrading its technologies and service, as Chinese consumers are paying more attention to oral health the past few years.
The therapy, the first and so far only oral drug approved in China for patients, made its market debut in the country last year, and was included in the national reimbursement drug list in August to make it more accessible.
"We will consider three new areas: water treatment, protein and human oral and gut health, which could bring new business opportunities," said Nielsen.
One is for a commercial small molecule oral solid dosage and the other for a biologics pilot facility.
This unique oral drug will help patients with asthma in China," he said.
Oral healthcare, sleep aids, male grooming products, and even kitchen appliances will likely see a spike in sales, he said.
Meanwhile, Wang found that ordinary toothpaste couldn't solve oral problems such as gingival bleeding, swelling and oral ulcers.
For example, oral care brand Saky took only about four years to rise from 14th to second place in the domestic toothbrush market.
China has become the first country worldwide to approve the oral anemia treatment hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
Last month, it released a new function of testing users’ oral English.
Aubagio, the first new oral drug for the treatment of multiple sclerosis, a rare disease of the nervous system characterized by loss of feeling and control of movement and speech, has been launched in China just prior to the expo, taking only 58 days from approval to launch and setting a record thanks to Chinese authorities' accelerated approval for new drug listings and launches, the company said.
The oral semaglutide will have its clinical trials next year.
We are working on artificial intelligence-enabled personal health solutions for products such as oral care, air and sleep innovations, as well as nutrition and mother and child care," he said.
Merck Healthcare currently sells and manufactures 16 medicines in China covering seven major therapeutic areas, including oral anti-diabetes, oncology, cardiovascular disorders, infertility and thyroid diseases.
Among its vast product line in various categories such as pain management, respiratory, oral care and more, Sensodyne, a toothpaste for people with sensitive teeth, is among its most quickly growing brands.
Zhang noted that two of the major growth drivers that will help fill the gap will be Tommee Tippee, Britain's largest nursing bottle producer that Jahwa acquired last May, and the partnership it established with Chinese traditional medicine manufacturer, Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd, in an attempt to tap into the oral care market.
Cibei, one of China's "hidden champion" manufacturer of oral and maxillo-facial implants, said it plans to intensify its research and development activities and export its upcoming product upgrades to economies covered by the Belt and Road Initiative.
Among them are its oral hygiene brands Oral-B and Crest, which are eyeing the opportunities brought by increasing awareness and demands for oral health among Chinese consumers.
Bringing the latest iO Series 3 electric toothbrush to the expo for its China debut, Oral-B hopes to contribute to the education of oral hygiene.
"P&G holds the corporate strategy of improving lives, and we are very committed to China as a market place where we see great potential," said Neal Reed, senior vice president of Oral Care Greater China at Procter & Gamble.
And unfortunately, we believe that about 89 percent of the Chinese population have cavity or oral health related issues.
"There is a huge opportunity for us here, and we are committed to unlocking it with a focus on trying to bring technology to drive sustainable daily habits that can help to empower consumers to improve their oral health," he said.
Health-related and nutritional products to boost the immune system are increasingly favored by Chinese shoppers, with the turnover of amino acid oral liquid and protein powder soaring 215 percent and 70 percent year-on-year, respectively.
They have their own oral language, but no written one.
During this year's Singles' Day shopping spree, the consumption of vaccine and oral health services increased by 20 times and 12 times, respectively, data from e-commerce giant JD.
"The upgrade of the China-New Zealand FTA will improve logistics efficiency and cut other operational costs, which in turn creates more value for businesses," said Leo Liu, general manager for China of Grin Natural Inc, an Auckland-based oral care brand.
Sinopharm's flagship respiratory disease products include Chinese patented drugs such as Jizhi Syrup and Sinusitis Oral Liquid, which are produced by its subsidiary Taiji Group.
The company said its production lines for two key products have been running 24/7 to ensure daily output of Jizhi Syrup of 6,500 boxes and 1,000 boxes of Sinusitis Oral Liquid.
Since December, it has delivered more than 323,300 boxes of Jizhi Syrup and more than 44,200 boxes of Sinusitis Oral Liquid nationwide to places including Beijing, Shanghai, and Jiangsu and Guangdong provinces.
China's oral care market is developing rapidly, thanks to rising awareness about oral health.
Chen Yin, a 30-year-old office clerk in Beijing, buys a wide range of oral care products, including electric toothbrushes, mouthwash, oral irrigators, mouth sprays and teeth whitening strips.
"I spend around 500 yuan ($69.3) on oral care every month.
Paying attention to oral hygiene not only prevents diseases, but is also a courtesy to others as it helps me maintain fresh breath," she said.
With 710 million people suffering from oral health problems, China's oral care market is expected to reach 128.5 billion yuan by the end of this year, or about 33.8 percent of the world, said a 2023 white paper on oral care released by Chinese e-commerce giant JD.
Competition among oral spray, tooth powder, and manual toothbrush categories players is fierce, the white paper said.
The high consumption group, users in smaller cities, new generation parents, Generation Z (people born between the mid-1990s and early 2010s) and women are the five typical consumer groups for oral care.
In addition, differentiated oral health problems, such as gum bleeding, halitosis, aphthous stomatitis, and children's tooth decay, have brought in diversified needs.
The survey showed that 83 percent of users use professional oral products when cleaning their oral cavity.
Up to 42 percent of users prioritize functionality while purchasing oral care products, rather than blindly pursuing cost-effectiveness.
"Currently, the oral care market in China has gone through the 1.0 stage of basic care, and the 2.0 stage of advanced care, transitioning to the 3.0 stage of refined care," said the white paper.
"With the constant improvement of people's living standards, the public's awareness of oral care is constantly awakening, and the demand for oral care is also becoming increasingly strong," said Wang Xinxue, a medical devices analyst at vbdata.
With diversified oral care demand from consumers, oral care is receiving increased attention from the capital market.
cn show that between 2021 and 2022, there were 23 investment deals in China's oral care market, with the total amount surpassing 1 billion yuan.
Apart from well-known oral care products such as electric toothbrushes and mouthwash, new product forms such as oral irrigators, tooth cleaners, whitening pens, and mouth sprays are also coming into play.
Among them, oral irrigators' gross merchandise volume contribution rate to the oral care industry has tripled in two years, a 2021 oral care report released by e-commerce behemoth Tmall showed.
Lian Minxiu, general manager of the oral care division of Philips China, said: "With the oral care industry booming, enterprises should ensure the quality of products, as consumers who have purchased low-quality products may raise concerns about the category, affecting their experience and forming misconceptions about the product, leading them to refuse a new way of achieving dental health in the future.
"Cong Jia, vice-president of investment at Bai Capital, said oral care products are in high demand.
"The bulk procurement program will promote the development of domestic dental implant brands, as it offers homegrown companies a good window period, during which two to three dark horses are expected to stand out," said Lyu Sang, a strategy consultant of Denfac, an oral medical device research and development enterprise based in Wuxi, Jiangsu province.
But now, orthodontics and teeth whitening have become the main businesses of the oral care industry.
Eyeing the huge market potential, pharmaceutical enterprises are ramping up efforts to grab a share of the COVID-19 preventative oral medicine market in China and the rest of the world.
On Jan 28, the COVID-19 oral medicine jointly developed by Nanjing-based Simcere Pharmaceutical Group Ltd and two institutes under the Chinese Academy of Sciences — the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology — was approved by the National Medical Products Administration for "treating mild to moderate adult COVID-19 patients".
The drug was the first globally approved COVID-19 oral drug made in China.
Meanwhile, Shanghai-based Junshi Biosciences also started clinical trials for COVID-19 preventative oral medicine.
Globally, US-based biopharmaceutical companies MSD and Pfizer started the research and development of COVID-19 oral drugs.
Currently, many COVID-19 preventative oral medicines await launch in the Chinese market.
Essence Securities estimated that various homegrown COVID-19 preventative oral drugs will be launched in the first quarter.
As reported by China Business Herald New Weekly, currently more than 100 Chinese enterprises are participating in the R&D of COVID-19 preventative oral medicine and there are more than 150 R&D projects.
With more supply to be provided, industry experts said the price of such drugs will be lowered in the future and that pharmaceutical enterprises offering COVID-19 preventative oral drugs plan to expand output.
Shanghai Junshi Biosciences Co Ltd announced in January that a study led by Ruijin Hospital, an affiliate of the Shanghai Jiao Tong University School of Medicine, indicated that an oral antiviral drug co-developed with several domestic organizations for treating COVID-19 has a shorter time in sustained clinical recovery with fewer safety concerns compared with Paxlovid, the antiviral COVID-19 pill developed by United States-based Pfizer.
So far, three oral antiviral medicines developed by Chinese drugmakers have been approved by China's health regulator to treat the disease.
Given the contagious Omicron variants, what might prove effective are mass-produced, low-cost small-molecule oral antiviral drugs that can be stored easily and accessed widely by outpatients, they said.